Conditions: HIV Infections
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 154
Healthy volunteers: no

Brief summary:
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).

Detailed description:

Arms:
arm 1: after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks arm 2: patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks

Interventions: intervention 1: tenofovir DF 300 mg QD intervention 2: tenofovir DF 300 mg QD intervention 3: emtricitabine 200 mg QD intervention 4: emtricitabine 200 mg QD intervention 5: Nevirapine 200 mg BID intervention 6: Atazanavir 300 mg intervention 7: Ritonavir 100 mg
Intervention descriptions: intervention 1: 300 mg QD intervention 2: 300 mg QD intervention 3: 200 mg QD intervention 4: 200 mg QD intervention 5: 200 mg BID intervention 6: 300 mg QD intervention 7: 100 mg QD

Protocol document: